Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Analyst Ratings
Strong Buy
21 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ALNY Stock 12 Month Forecast
Average Price Target
$419.61
▲(4.43%Upside)
| Highest Price Target$550.00 | Average Price Target$419.61 | Lowest Price Target$280.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$422
Hold
5.03%
Upside
Reiterated
08/01/25
Alnylam Pharma's overall score is driven by strong earnings call results and positive corporate events, reflecting growth potential and strategic initiatives. However, ongoing financial performance challenges and valuation concerns weigh down the score. Technical indicators show strong momentum but caution for potential pullback due to overbought conditions.
TD Cowen
$371→$482
Buy
19.96%
Upside
Assigned
08/01/25
Alnylam Pharma's Strong Financial Performance and Strategic Partnerships Justify Buy RatingWe are increasing our NPV-based PT to $482 from a prior $371 based on a faster than previously modeled ramp to peak Amvuttra/TTR-CM franchise sales, as supported by the breakaway 2Q Amvuttra revenue. ALNY On Track For GAAP FY25 combined net product rev guidance was raised to $2.65B-$2.8B, from a prior $2.05B-$2.25B, and positions ALNY to achieve non-GAAP profitability, and GAAP breakeven this year. We model 4Q25 GAAP EPS of (0.01). 2Q25 rev growth was primarily by Amvuttra expansion into TTR-CM.
Canaccord Genuity
$390→$415
Buy
3.29%
Upside
Reiterated
08/01/25
Raymond James
$308→$424
Buy
5.53%
Upside
Reiterated
08/01/25
Truist Financial
$385→$459
Buy
14.24%
Upside
Reiterated
08/01/25
Barclays
$329→$460
Buy
14.48%
Upside
Reiterated
08/01/25
Stifel Nicolaus
$345→$441
Buy
9.76%
Upside
Reiterated
08/01/25
Wells Fargo
$333→$395
Hold
-1.69%
Downside
Reiterated
08/01/25
Scotiabank
$342→$450
Buy
12.00%
Upside
Reiterated
08/01/25
UBS
$403→$550
Buy
36.88%
Upside
Reiterated
08/01/25
Piper Sandler
$304→$449
Buy
11.75%
Upside
Reiterated
08/01/25
William Blair
―
Buy
―
Reiterated
07/31/25
Needham
$377→$478
Buy
18.96%
Upside
Reiterated
07/31/25
Alnylam Pharma's Strong Q2 2025 Performance and Raised Guidance Justify Buy Rating and Increased Price TargetWe are raising our revenue estimates and PT to $478 on the back of the early but strong Amvuttra ATTR-CM launch. We also model sustainable non-GAAP profitability starting in 2025. Disclaimers JOSEPH STRINGER, PH.D.
Chardan Capital
$325→$400
Buy
-0.45%
Downside
Reiterated
07/31/25
Morgan Stanley
$312→$405
Hold
0.80%
Upside
Reiterated
07/31/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$422
Hold
5.03%
Upside
Reiterated
08/01/25
Alnylam Pharma's overall score is driven by strong earnings call results and positive corporate events, reflecting growth potential and strategic initiatives. However, ongoing financial performance challenges and valuation concerns weigh down the score. Technical indicators show strong momentum but caution for potential pullback due to overbought conditions.
TD Cowen
$371→$482
Buy
19.96%
Upside
Assigned
08/01/25
Alnylam Pharma's Strong Financial Performance and Strategic Partnerships Justify Buy RatingWe are increasing our NPV-based PT to $482 from a prior $371 based on a faster than previously modeled ramp to peak Amvuttra/TTR-CM franchise sales, as supported by the breakaway 2Q Amvuttra revenue. ALNY On Track For GAAP FY25 combined net product rev guidance was raised to $2.65B-$2.8B, from a prior $2.05B-$2.25B, and positions ALNY to achieve non-GAAP profitability, and GAAP breakeven this year. We model 4Q25 GAAP EPS of (0.01). 2Q25 rev growth was primarily by Amvuttra expansion into TTR-CM.
Canaccord Genuity
$390→$415
Buy
3.29%
Upside
Reiterated
08/01/25
Raymond James
$308→$424
Buy
5.53%
Upside
Reiterated
08/01/25
Truist Financial
$385→$459
Buy
14.24%
Upside
Reiterated
08/01/25
Barclays
$329→$460
Buy
14.48%
Upside
Reiterated
08/01/25
Stifel Nicolaus
$345→$441
Buy
9.76%
Upside
Reiterated
08/01/25
Wells Fargo
$333→$395
Hold
-1.69%
Downside
Reiterated
08/01/25
Scotiabank
$342→$450
Buy
12.00%
Upside
Reiterated
08/01/25
UBS
$403→$550
Buy
36.88%
Upside
Reiterated
08/01/25
Piper Sandler
$304→$449
Buy
11.75%
Upside
Reiterated
08/01/25
William Blair
―
Buy
―
Reiterated
07/31/25
Needham
$377→$478
Buy
18.96%
Upside
Reiterated
07/31/25
Alnylam Pharma's Strong Q2 2025 Performance and Raised Guidance Justify Buy Rating and Increased Price TargetWe are raising our revenue estimates and PT to $478 on the back of the early but strong Amvuttra ATTR-CM launch. We also model sustainable non-GAAP profitability starting in 2025. Disclaimers JOSEPH STRINGER, PH.D.
Chardan Capital
$325→$400
Buy
-0.45%
Downside
Reiterated
07/31/25
Morgan Stanley
$312→$405
Hold
0.80%
Upside
Reiterated
07/31/25
Best Analysts Covering Alnylam Pharma
1 Month
xxx
Success Rate
20/35 ratings generated profit
Average Return
+0.83%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +0.83% per trade.
3 Months
xxx
Success Rate
21/31 ratings generated profit
Average Return
+11.37%
assigned a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 67.74% of your transactions generating a profit, with an average return of +11.37% per trade.
1 Year
Success Rate
20/22 ratings generated profit
Average Return
+36.01%
reiterated a buy rating 5 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +36.01% per trade.
2 Years
xxx
Success Rate
22/22 ratings generated profit
Average Return
+79.42%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +79.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ALNY Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
9
6
5
3
1
Buy
48
51
35
40
30
Hold
14
12
10
11
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
71
69
50
54
42
Each month's total comprises the sum of three months' worth of ratings.
ALNY Financial Forecast
ALNY Stock Forecast FAQ
What is ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 419.61.
What is ALNY’s upside potential, based on the analysts’ average price target?
Alnylam Pharmaceuticals has 4.43% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALNY a Buy, Sell or Hold?
Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 21 buy ratings, 4 hold ratings and 0 sell ratings.
What is Alnylam Pharmaceuticals’s price target?
The average price target for Alnylam Pharmaceuticals is 419.61. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $550.00 ,the lowest forecast is $280.00. The average price target represents 4.43% Increase from the current price of $401.8.
The highest analyst price target is $550.00 ,the lowest forecast is $280.00. The average price target represents 4.43% Increase from the current price of $401.8.
What do analysts say about Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.
How can I buy shares of ALNY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.